Fig. 1From: Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysisPRISMA flow diagram. MA meta-analysis, NMA network meta-analysis, OS overall survival, PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCT randomized controlled trial, SLR systematic literature reviewBack to article page